Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Adult male and female participants who voluntarily sign the informed consent.~* Fasting lipid results following greater than 12-hour fasting period:~  * Triglycerides level greater than or equal to 150 mg/dL,~ * High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and~ * Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL.~* Participant must agree to utilize adequate birth control methods and adhere to the American Heart Association (AHA) diet.~Exclusion Criteria~* Participants with unstable medical conditions, medical conditions considered inappropriate in a clinical trial, or participants who are taking excluded concomitant medications are not allowed in the study.~* Participants receiving coumarin anticoagulants or systemic cyclosporine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 and Rosuvastatin Calcium (Type: EXPERIMENTAL): ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
- ABT-335 (Type: ACTIVE_COMPARATOR): ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
- Rosuvastatin Calcium (Type: ACTIVE_COMPARATOR): Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).